JP2008546714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008546714A5 JP2008546714A5 JP2008517187A JP2008517187A JP2008546714A5 JP 2008546714 A5 JP2008546714 A5 JP 2008546714A5 JP 2008517187 A JP2008517187 A JP 2008517187A JP 2008517187 A JP2008517187 A JP 2008517187A JP 2008546714 A5 JP2008546714 A5 JP 2008546714A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- therapeutic agent
- agent according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 208000022461 Glomerular disease Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 231100000852 glomerular disease Toxicity 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 210000003584 mesangial cell Anatomy 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 201000000274 Carcinosarcoma Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 208000028387 Felty syndrome Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000035268 Mast Cell Activation disease Diseases 0.000 claims 1
- 208000005410 Mediastinal Neoplasms Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 208000013901 Nephropathies and tubular disease Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 241001364096 Pachycephalidae Species 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 208000021161 Plasma cell disease Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000011529 cardiovascular cancer Diseases 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 208000027138 indeterminate colitis Diseases 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 201000000349 mediastinal cancer Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002071 myeloproliferative effect Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000009571 retroperitoneal cancer Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69156305P | 2005-06-17 | 2005-06-17 | |
| US60/691,563 | 2005-06-17 | ||
| PCT/US2006/023645 WO2006138660A2 (en) | 2005-06-17 | 2006-06-15 | Sphingosine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008546714A JP2008546714A (ja) | 2008-12-25 |
| JP2008546714A5 true JP2008546714A5 (https=) | 2009-07-30 |
| JP5368789B2 JP5368789B2 (ja) | 2013-12-18 |
Family
ID=37106302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008517187A Active JP5368789B2 (ja) | 2005-06-17 | 2006-06-15 | スフィンゴシンキナーゼ阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7338961B2 (https=) |
| EP (2) | EP2314574A1 (https=) |
| JP (1) | JP5368789B2 (https=) |
| KR (1) | KR101386282B1 (https=) |
| CN (1) | CN101248041B (https=) |
| AU (1) | AU2006261327B2 (https=) |
| BR (1) | BRPI0611966B1 (https=) |
| CA (1) | CA2612338C (https=) |
| ES (1) | ES2528451T3 (https=) |
| IL (1) | IL187881A (https=) |
| MX (1) | MX2007015863A (https=) |
| RU (1) | RU2447060C2 (https=) |
| WO (1) | WO2006138660A2 (https=) |
| ZA (1) | ZA200800423B (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| WO2006050264A1 (en) | 2004-10-29 | 2006-05-11 | Musc Foundation For Research Development | Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer |
| WO2006050265A2 (en) | 2004-10-29 | 2006-05-11 | Musc Foundation For Research Development | Ceramides and apoptosis-signaling ligand |
| US8324237B2 (en) * | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| CN101248041B (zh) * | 2005-06-17 | 2013-11-20 | 艾宝奇生物工艺有限公司 | 鞘氨醇激酶抑制剂 |
| MY149143A (en) * | 2006-01-18 | 2013-07-15 | Amgen Inc | Thiazole compounds as protien kinase b (pkb) inhibitors |
| EP2141990A4 (en) * | 2007-03-28 | 2011-07-06 | High Point Pharmaceuticals Llc | ACTIVE COMPOUNDS ON 11BETA-HSD1 |
| AU2008276512A1 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| US8372888B2 (en) * | 2008-04-29 | 2013-02-12 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, compositions and processes for using same |
| US8314151B2 (en) | 2008-04-29 | 2012-11-20 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, and processes for using same |
| US20110275673A1 (en) * | 2008-09-19 | 2011-11-10 | Yibin Xiang | Inhibitors of sphingosine kinase 1 |
| EP2166094A1 (en) | 2008-09-23 | 2010-03-24 | Ecole Normale Superieure De Lyon | Methods for prolonging the health benefits triggered by a dietary restriction using a sphingosine kinase inhibitor |
| CA2742866C (en) | 2008-11-06 | 2017-10-24 | Musc Foundation For Research Development | Lysosomotropic inhibitors of acid ceramidase |
| PL2405751T3 (pl) | 2009-03-12 | 2016-01-29 | Apogee Biotechnology Corp | Proleki inhibitorów kinazy sfingozyny |
| WO2010129954A1 (en) * | 2009-05-08 | 2010-11-11 | Apogee Biotechnology Corporation | Treatment of ischemia-reperfusion injury |
| WO2011020116A1 (en) | 2009-08-14 | 2011-02-17 | University Of Virginia Patent Foundation | Imidamide sphingosine kinase inhibitors |
| US9062015B2 (en) * | 2009-12-14 | 2015-06-23 | Merck Patent Gmbh | Inhibitors of sphingosine kinase |
| JPWO2012121168A1 (ja) * | 2011-03-04 | 2014-07-17 | 国立大学法人京都大学 | キナーゼ阻害剤 |
| RU2461544C1 (ru) * | 2011-04-19 | 2012-09-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вирусологии им. Д.И. Ивановского" Министерства здравоохранения и социального развития Российской Федерации | Производные 1-(1-адамантил)этиламина и их противовирусная активность |
| EP2822548B1 (en) | 2012-02-08 | 2019-04-24 | University of Virginia Patent Foundation | Long chain base sphingosine kinase inhibitors |
| RU2524216C1 (ru) * | 2013-04-09 | 2014-07-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вирусологии им. Д.И. Ивановского" Министерства здравоохранения Российской Федерации | Пептидные производные 1-(1-адамантил)этиламина и их противовирусное действие |
| RU2529201C1 (ru) * | 2013-06-18 | 2014-09-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный технический университет" (ВолгГТУ) | Способ получения n-(2-гетероциклоалкил-1-илэтил)адамантан-2-аминов |
| EP3201181B1 (en) | 2014-10-01 | 2020-12-02 | Virginia Tech Intellectual Properties, Inc. | Sphingosine kinase inhibitors |
| CN107106525B (zh) * | 2014-10-24 | 2021-03-19 | 红山生物医药有限公司 | 用于抑制单链rna病毒复制的治疗 |
| EP3223807B1 (en) | 2014-11-24 | 2021-09-15 | The Board of Trustees of the University of Illinois | Method of preventing or treating a pulmonary disease or condition |
| WO2016110595A1 (en) * | 2015-01-09 | 2016-07-14 | Atonomics A/S | A UNIVERSAL ASSAY FOR DETERMINING THE QUANTITY OF TNFα INHIBITORY DRUGS AND THEIR CORRESPONDING ANTI-DRUG-ANTIBODIES |
| CN104529859B (zh) * | 2015-01-13 | 2016-08-17 | 佛山市赛维斯医药科技有限公司 | 含苯胺和二烯氟代金刚烷结构的化合物、其制备方法和用途 |
| CA2997671A1 (en) * | 2015-10-06 | 2017-04-13 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| RU2605698C1 (ru) * | 2015-12-23 | 2016-12-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ) | Производные 2-(адамант-2-ил)этиламина, обладающие потенциальной противовирусной активностью |
| AU2017208970A1 (en) * | 2016-01-18 | 2018-08-02 | Arisan Therapeutics | Adamatane derivatives for the treatment of filovirus infection |
| JP6902040B2 (ja) | 2016-01-28 | 2021-07-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 免疫チェックポイント阻害剤の効力を増強する方法 |
| US11180489B2 (en) | 2016-03-30 | 2021-11-23 | U niversity of Virginia Patent Foundation | Sphingosine kinase inhibitor amidoxime prodrugs |
| WO2017218421A1 (en) * | 2016-06-13 | 2017-12-21 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| EP3482199A1 (en) * | 2016-07-08 | 2019-05-15 | Atonomics A/S | A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples |
| WO2018237379A2 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| WO2019018185A1 (en) * | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS |
| WO2019140254A1 (en) * | 2018-01-12 | 2019-07-18 | President And Fellows Of Harvard College | Multicyclic compounds and use of same for treating tuberculosis |
| US11261201B2 (en) | 2018-01-12 | 2022-03-01 | President And Fellows Of Harvard College | TRNA synthetase inhibitors |
| US20210080467A1 (en) | 2018-02-21 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors |
| AU2019101780A4 (en) * | 2018-05-02 | 2021-04-15 | Sun Yat-Sen University | Use of SPHK2 inhibitor as drug for repairing bone marrow hematopoietic system injury or treating bone marrow hematopoietic dysfunction |
| RU2732297C2 (ru) * | 2018-11-14 | 2020-09-15 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Производные нестероидных противовоспалительных средств |
| CN111233887A (zh) * | 2018-11-28 | 2020-06-05 | 武汉武药科技有限公司 | 一种盐酸多佐胺中间体的合成工艺 |
| KR102887366B1 (ko) * | 2019-01-04 | 2025-11-14 | (주)아모레퍼시픽 | 아다만탄 카르복실산 벤질 아마이드 유도체 화합물 및 그를 포함하는 피부 미백용 조성물 |
| KR20210118101A (ko) * | 2019-01-16 | 2021-09-29 | 아포지 바이오테크놀로지 코포레이션 | 항암 면역 반응을 유도하는 방법 |
| RU2697409C1 (ru) * | 2019-04-30 | 2019-08-14 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | 1-Адамантил-3-(((1R,4aS,10aR)-7-изопропил-1,4а-диметил-1,2,3,4,4а,9,10,10а-октагидрофенантрен-1-ил)метил)мочевина, проявляющая ингибирующее действие в отношении фермента тирозил-ДНК-фосфодиэстеразы 1 человека и увеличивающая активность темозоломида в отношении клеток глиобластомы |
| CN110330452A (zh) * | 2019-06-12 | 2019-10-15 | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 四氢吡咯烷类化合物或其药学上可接受的盐及其制备方法和应用 |
| CN110483284B (zh) * | 2019-08-26 | 2022-05-13 | 浙江工业大学 | 一种1-金刚烷甲酸-2-(取代苯甲酰氧基)乙酯类化合物及其合成方法和应用 |
| EP4117630A4 (en) | 2020-03-10 | 2024-07-03 | RedHill Biopharma Ltd. | TREATMENT OF CORONAVIRUS INFECTIONS |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CN112336863A (zh) * | 2020-11-26 | 2021-02-09 | 中山大学附属第八医院（深圳福田） | S1p受体抑制剂在制备防治强直性脊柱炎产品中的应用 |
| US11471448B2 (en) | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
| CN116217468A (zh) * | 2023-02-22 | 2023-06-06 | 天津民祥药业有限公司 | 一种奥帕尼布的新型合成方法 |
| WO2026035293A1 (en) | 2024-08-06 | 2026-02-12 | Apogee Biotechnology Corporation | Compositions and methods for the prevention and treatment of obesity and obesity-induced disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3352912A (en) * | 1963-07-24 | 1967-11-14 | Du Pont | Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes |
| US3663565A (en) | 1969-07-02 | 1972-05-16 | Searle & Co | Esters and amides of 3-phenyladamantane-1-carboxylic acid |
| US3657273A (en) * | 1970-05-01 | 1972-04-18 | Searle & Co | Adamantane-1 3-dicarboxamides |
| BE791392A (fr) * | 1971-11-15 | 1973-05-14 | Scherico Ltd | Aryl- et aralcoylamides substitues |
| US4053509A (en) * | 1971-11-15 | 1977-10-11 | Schering Corporation | Substituted aryl and aralkyl amides |
| SU451691A1 (ru) * | 1973-03-27 | 1974-11-30 | Киевский Ордена Ленина Политехнический Институт Им.50-Летия Великой Октябрьской Социалистической Революции | Способ получени -метилстеариламидов адамантанкарбоновых кислот |
| US4349552A (en) * | 1978-10-30 | 1982-09-14 | Fujisawa Pharmaceutical Company, Ltd. | 5-Fluorouracil derivatives, and their pharmaceutical compositions |
| JPS5671075A (en) * | 1979-11-12 | 1981-06-13 | Sumitomo Chem Co Ltd | Novel imidazole derivative |
| CA1228346A (en) * | 1983-10-07 | 1987-10-20 | George M. Kramer | Adamantylamine/long chain alkylamine catalysts and use in paraffin-olefin alkylation process |
| SU1367194A1 (ru) * | 1984-03-16 | 1996-04-10 | В.Ю. Ковтун | Литиевая соль 1-адамантанкарбоновой кислоты, обладающая психостимулирующей активностью |
| SU1574586A1 (ru) * | 1988-06-20 | 1990-06-30 | Институт Биоорганической Химии Ан Усср | Способ получени замещенных бромом адамантан-1-карбоновых кислот |
| DE58905637D1 (de) * | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
| JP2511573B2 (ja) * | 1990-11-29 | 1996-06-26 | 川崎製鉄株式会社 | １―エチルアダマンタンの製造方法 |
| JPH04322743A (ja) * | 1991-04-24 | 1992-11-12 | Kawasaki Steel Corp | アルキルアダマンタン類の製造用触媒およびこれを用いたアルキルアダマンタン類の製造方法 |
| JPH04330947A (ja) * | 1991-05-02 | 1992-11-18 | Kawasaki Steel Corp | １−ビニルアダマンタン製造用触媒およびこれを用いた１−ビニルアダマンタンの製造方法 |
| NZ252717A (en) * | 1992-05-15 | 1996-05-28 | British Tech Group | Adamantane-pyridine derivatives and medicaments |
| JP2001524468A (ja) * | 1997-11-21 | 2001-12-04 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト |
| CN100390178C (zh) * | 1999-11-12 | 2008-05-28 | 拜奥根Idec马萨诸塞公司 | 作为腺苷受体拮抗剂的多环烷基嘌呤 |
| JP4271348B2 (ja) * | 2000-06-16 | 2009-06-03 | 出光興産株式会社 | １，３−アダマンタンジカルボン酸ジ−ｔｅｒｔ−ブチルの製造方法 |
| RU2197467C2 (ru) * | 2000-11-09 | 2003-01-27 | Институт нефтехимии и катализа АН РБ и УНЦ РАН | Способ получения 1-хлор-3-ацетил- и 1,3-дихлор-5-ацетиладамантанов |
| AU2003245555A1 (en) * | 2002-06-17 | 2003-12-31 | The Pennsylvania State Research Foundation | Sphingosine kinase inhibitors |
| US20040116479A1 (en) * | 2002-10-04 | 2004-06-17 | Fortuna Haviv | Method of inhibiting angiogenesis |
| EP1615667A2 (en) * | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| ATE467616T1 (de) * | 2003-04-11 | 2010-05-15 | High Point Pharmaceuticals Llc | Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase |
| JP2008518903A (ja) * | 2004-11-02 | 2008-06-05 | ファイザー・インク | 置換および非置換アダマンチルアミドの新規化合物 |
| GB0506133D0 (en) * | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
| US8324237B2 (en) * | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| US20060270631A1 (en) * | 2005-05-26 | 2006-11-30 | Smith Charles D | Methods for the treatment and prevention of angiogenic diseases |
| CN101248041B (zh) * | 2005-06-17 | 2013-11-20 | 艾宝奇生物工艺有限公司 | 鞘氨醇激酶抑制剂 |
| PL2405751T3 (pl) * | 2009-03-12 | 2016-01-29 | Apogee Biotechnology Corp | Proleki inhibitorów kinazy sfingozyny |
| WO2010129954A1 (en) * | 2009-05-08 | 2010-11-11 | Apogee Biotechnology Corporation | Treatment of ischemia-reperfusion injury |
-
2006
- 2006-06-15 CN CN2006800289405A patent/CN101248041B/zh active Active
- 2006-06-15 EP EP10010228A patent/EP2314574A1/en not_active Withdrawn
- 2006-06-15 CA CA2612338A patent/CA2612338C/en active Active
- 2006-06-15 JP JP2008517187A patent/JP5368789B2/ja active Active
- 2006-06-15 AU AU2006261327A patent/AU2006261327B2/en active Active
- 2006-06-15 RU RU2008100606/04A patent/RU2447060C2/ru active
- 2006-06-15 BR BRPI0611966-2A patent/BRPI0611966B1/pt active IP Right Grant
- 2006-06-15 KR KR1020087001258A patent/KR101386282B1/ko active Active
- 2006-06-15 MX MX2007015863A patent/MX2007015863A/es active IP Right Grant
- 2006-06-15 EP EP06785051.1A patent/EP1904439B1/en active Active
- 2006-06-15 WO PCT/US2006/023645 patent/WO2006138660A2/en not_active Ceased
- 2006-06-15 ES ES06785051.1T patent/ES2528451T3/es active Active
- 2006-06-15 US US11/424,423 patent/US7338961B2/en not_active Ceased
-
2007
- 2007-12-04 IL IL187881A patent/IL187881A/en active IP Right Grant
- 2007-12-23 US US11/963,838 patent/US8063248B2/en active Active
-
2008
- 2008-01-15 ZA ZA200800423A patent/ZA200800423B/xx unknown
-
2011
- 2011-10-19 US US13/277,044 patent/US8557800B2/en active Active
-
2022
- 2022-03-07 US US17/688,814 patent/USRE49811E1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008546714A5 (https=) | ||
| HRP20200974T1 (hr) | Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koji ih sadrže i njihova upotreba za pripravu lijekova | |
| JP2011525502A5 (https=) | ||
| JP2020506899A5 (https=) | ||
| JP2016540749A5 (https=) | ||
| JP2014512406A5 (https=) | ||
| JP2013116921A5 (https=) | ||
| CL2011001754A1 (es) | Compuestos derivados de pirido pirazina, inhibidores de poli (adp-ribosa) polimerasa (parp); composicion y combinacion farmaceutica; y uso para el tratamiento de enfermedades o condiciones tales como cancer, enfermedades cardiovasculares, metabolicas, inflamatorias y neurodegenerativas. | |
| JP2017071634A5 (https=) | ||
| JP2019532079A5 (https=) | ||
| JP2013519684A5 (https=) | ||
| JP2018524367A5 (https=) | ||
| JP2014521625A5 (https=) | ||
| HRP20170826T1 (hr) | 5-fenil-[1,2,4]triazolo[1,5-a]piridin-2-il karboksamidi kao inhibitori jak | |
| HRP20211002T1 (hr) | 1,3-tiazol-2-il supstituirani benzamidi | |
| JP2012509903A5 (https=) | ||
| JP2017521469A5 (https=) | ||
| DE602007009807D1 (de) | Sulfonylbenzimidazolderivate | |
| JP2017519027A5 (https=) | ||
| NZ601924A (en) | 4-phenyl pyridine analogues as protein kinase inhibitors | |
| JP2010540562A5 (https=) | ||
| JP2016507581A5 (https=) | ||
| RU2010108470A (ru) | Соединения фенилуксусной кислоты | |
| EA200970852A1 (ru) | Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы | |
| JP2009510097A5 (https=) |